Derfuss, TobiasCurtin, FrançoisGuebelin, ClaudiaBridel, ClaireRasenack, MariaMatthey, AlainDu Pasquier, RenaudSchluep, MyriamDesmeules, JulesLang, Alois B.Perron, HervéFaucard, RaphaelPorchet, HervéHartung, Hans-PeterKappos, LudwigLalive, Patrice H.2015-07-142015-07-142015-08Derfuss, T, Curtin, F, Guebelin, C, Bridel, C, Rasenack, M, Matthey, A, Du Pasquier, R, Schluep, M et al 2015, 'A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — a twelve month follow-up', Journal of Neuroimmunology, vol. 285, pp. 68-70.0165-5728 (print)1872-8421 (online)10.1016/j.jneuroim.2015.05.019http://hdl.handle.net/2263/48660GNbAC1 is a humanized monoclonal antibody targeting MSRV-Env, an endogenous retroviral protein, which is expressed inmultiple sclerosis (MS) lesions, is pro-inflammatory and inhibits oligodendrocyte precursor cell differentiation. This paper describes the open-label extension up to 12 months of a trial testing GNbAC1 in 10 MS patients at 2 and 6 mg/kg. The primary objective was to assess GNbAC1 safety, and other objectives were pharmacokinetic and pharmacodynamic assessments. During the extended study, no safety issues occurred in the 8 remaining patients. No anti-GNbAC1 antibodies were detected. GNbAC1 appears well tolerated.en© 2015 Elsevier B.V. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Journal of Neuroimmunology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Neuroimmunology, vol. 285, pp. 68-70, 2015. doi :10.1016/j.jneuroim.2015.05.019Human endogenous retrovirus (HERV)Monoclonal antibody (MAb)Clinical trialSafetyMultiple sclerosis (MS)Postprint Article